“Croquis” Targeting the Global Market with Evidence-Based Marketing
September 4th, 2020
Samyang Biopharm, a biomedical affiliate of Samyang Group, is pressing ahead to build the global footing for the thread lift brand, “Croquis,” with evidence-based marketing. Last year, Samyang Biopharm successfully developed Croquis, received a CE mark which is necessary to enter the EU market, and began to target the global market.
Last month, the company also successfully made its first debut in IMCAS World Congress 2020. Throughout the course of the congress, 900 participants from 81 countries visited the booth set up by Samyang Biopharmam. Currently, the company is discussing specific conditions with distributors in the UK, France, and Russia.
Samyang Biopharm overcame disadvantages as a late comer in data-oriented and evidence-based marketing and is earning trust in the international aesthetic market. While traditional aesthetic thread brands only compare and emphasize preoperative and postoperative effects,
Samyang Biopharm aims towards evidence-based marketing, putting in efforts to obtain data about not only operative effects by part of the face but also the thread’s physical properties.
Currently, Samyang Biopharm is conducting a study with dermatologists and plastic surgeons in the US, France, and Spain with the goal of obtaining data on the thread’s physical properties, including the thread’s elasticity and strength, to reaffirm Croquis’s safety and efficacy and to produce optimal effects for each part of the face. The interim study results will be presented to physicians around the world at global conferences including AMWC.
An official from Samyang Biopharm said, “The aesthetic medicine business of Samyang Biopharm is aiming towards producing art technology, which represents the convergence between art and technology. Based on the technologies Samyang Biopharm has built, we will materialize natural beauty.”
Meanwhile, Samyang Biopharm is conducting a clinical trial on the biodegradable polymer PCL filler in Korea for its launch next year.
Samyang Biopharm expects that while the mainstream products containing HA demonstrate effects for 6 months, the PCL filler can remain effective for up to 24 months. The company aims to improve volume retention and safety compared to other existing products.
Last month, the company also successfully made its first debut in IMCAS World Congress 2020. Throughout the course of the congress, 900 participants from 81 countries visited the booth set up by Samyang Biopharmam. Currently, the company is discussing specific conditions with distributors in the UK, France, and Russia.
Samyang Biopharm overcame disadvantages as a late comer in data-oriented and evidence-based marketing and is earning trust in the international aesthetic market. While traditional aesthetic thread brands only compare and emphasize preoperative and postoperative effects,
Samyang Biopharm aims towards evidence-based marketing, putting in efforts to obtain data about not only operative effects by part of the face but also the thread’s physical properties.
Currently, Samyang Biopharm is conducting a study with dermatologists and plastic surgeons in the US, France, and Spain with the goal of obtaining data on the thread’s physical properties, including the thread’s elasticity and strength, to reaffirm Croquis’s safety and efficacy and to produce optimal effects for each part of the face. The interim study results will be presented to physicians around the world at global conferences including AMWC.
An official from Samyang Biopharm said, “The aesthetic medicine business of Samyang Biopharm is aiming towards producing art technology, which represents the convergence between art and technology. Based on the technologies Samyang Biopharm has built, we will materialize natural beauty.”
Meanwhile, Samyang Biopharm is conducting a clinical trial on the biodegradable polymer PCL filler in Korea for its launch next year.
Samyang Biopharm expects that while the mainstream products containing HA demonstrate effects for 6 months, the PCL filler can remain effective for up to 24 months. The company aims to improve volume retention and safety compared to other existing products.
